Collaboration leverages expertise in artificial intelligence from Genentech and NVIDIA to unlock scientific innovation and empower R&D at a scale previously unattainable in pursuit of novel therapies.

Encouraging preliminary data from the ongoing DIPG clinical study to be presented at the 2023 Society for Neuro-Oncology Annual Meeting in Vancouver.

Glox Therapeutics, announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria.

Armis Biopharma, Inc. announced that the company received a $20.3 million contract from the Defense Threat Reduction Agency (DTRA) to develop its proprietary Veriox® DECON chemical warfare agent (CWA) decontamination product.

A team of scientists have developed a protocol for the fabrication of a 3D microfluidic neuromuscular platform that can be used to model Motor Neuron Diseases (MND’s).

Clinical Trial Application filed for combined drug targeting amyloid deposits associated with Alzheimer’s Disease.